{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-073326","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.369000+00:00","generated_at":"2026-06-01T04:27:31.430038+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"enGene Q2 net loss $15.0M; plans EG-70 trial expansion for papillary-only NMIBC","bullets":["Net loss of $15.0M ($0.38/share) vs $6.5M ($9.30/share) YoY; operating expenses $17.3M (up from $4.7M).","Cash and equivalents $264.8M; expects to fund operations into 2027.","Interim LEGEND cohort data (BCG-unresponsive ~20 patients) expected by end of Sep 2024; BLA mid-2026.","Plans to expand LEGEND with third cohort (70-100 patients) for papillary-only NMIBC, enrollment Q4 2024.","Deprioritized cystic fibrosis program EG-i08; Paul Hastings and Wouter Joustra elected to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-073326","json":"https://secwatch.observer/filing/0000950170-24-073326.json","markdown":"https://secwatch.observer/filing/0000950170-24-073326.md","text":"https://secwatch.observer/filing/0000950170-24-073326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024073326/0000950170-24-073326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024073326/engn-20240614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:27:31.430038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}